Background
==========

Coronary heart disease (CHD), including its severe sequelae, myocardial infarction (MI), is the leading cause of disease-related morbidity and mortality worldwide, and accounts for approximately 7 million deaths each year \[[@b1-medscimonit-22-2999],[@b2-medscimonit-22-2999]\]. CHD is a multifactorial disease, with both environmental and genetic factors involved \[[@b3-medscimonit-22-2999]--[@b5-medscimonit-22-2999]\]. The key risk factors for CHD are smoking, family history, hypertension, obesity, diabetes, sedentary behavior, hyperlipidemia, and low-density lipoprotein cholesterol (LDL-C) \[[@b6-medscimonit-22-2999]--[@b8-medscimonit-22-2999]\]. With advancing age, inflammatory deposits or atherosclerotic plaques coat the walls of arteries supplying blood and oxygen to the heart and consequently severely restrict blood supply, causing angina, and shortness of breath; plaques rupture or break, causing heart attack and myocardial infarction, which severely diminishes heart function and is often fatal \[[@b9-medscimonit-22-2999],[@b10-medscimonit-22-2999]\]. Atherosclerotic inflammation is the critical factor in formation of coronary plaques and the progression of plaques to an unstable state, resulting in MI \[[@b11-medscimonit-22-2999]\]. In the past decade, the influence of genetic factors in the development of CHD has been widely investigated \[[@b12-medscimonit-22-2999]\].

*Adenosine triphosphate-binding cassette transporter A1 (ABCA1*) belongs to the ATP-binding cassette super family, and single-nucleotide polymorphisms (SNPs) have been discovered in this gene that are relevant to human disease conditions \[[@b13-medscimonit-22-2999],[@b14-medscimonit-22-2999]\]. In particular, mutations in this gene lead to heritable high-density lipoprotein (HDL) disorder and Tangier disease, both of which are associated with increased risk of early-onset CHD \[[@b4-medscimonit-22-2999],[@b15-medscimonit-22-2999],[@b16-medscimonit-22-2999]\]. Among the *ABSC1* SNPs, R219K polymorphism occurs in the coding region, leading to an amino acid substitution from arginine to lysine in exon 7 (rs2230806), and is widely studied for its association with susceptibility to CHD \[[@b17-medscimonit-22-2999]\]. The C-reactive protein gene (*CRP)* is mapped to chromosome 1q21 to 1q23 within a conserved genetic region spanning approximately 1.9 kb \[[@b18-medscimonit-22-2999],[@b19-medscimonit-22-2999]\]. Elevated levels of serum CRP reflect an inflammatory state and CRP itself participates in inflammation responses; and its circulating concentration is a sensitive marker for cardiovascular disease risk \[[@b20-medscimonit-22-2999]\]. Previous studies reported that SNPs in *CRP* alter CRP levels in plasma and, since CRP protein is present in atherosclerotic plaques, where it elicits pro-inflammatory and atherogenic outcomes, SNPs in *CRP* are of direct relevance to CHD risk \[[@b20-medscimonit-22-2999]--[@b22-medscimonit-22-2999]\]. Although the precise role of genetic factors in susceptibility to CHD remains unclear, the role of *CRP* and *ABCA1* gene polymorphisms in CHD susceptibility is of significant interest due to their high clinical value. However, a few previous studies noted no significant association of *CRP* gene polymorphisms with the susceptibility to CHD \[[@b23-medscimonit-22-2999],[@b24-medscimonit-22-2999]\], but other studies showed a significant association of *CRP* and *ABCA1* gene polymorphisms with CHD susceptibility \[[@b20-medscimonit-22-2999],[@b21-medscimonit-22-2999]\]. To address the conflicting data and to investigate the role of *CRP* and *ABCA1* gene polymorphisms in CHD susceptibility, we studied 1059G \>C SNP in exon 2 of *CRP* and R219K (rs2230806) polymorphism of *ABCA1*in this meta-analysis.

Material and Methods
====================

Data sources and keywords
-------------------------

To identify relevant published studies, the electronic databases PubMed, Springer link, Wiley, EBSCO, Ovid, Wanfang database, VIP database, and China National Knowledge Infrastructure (CNKI) were searched exhaustively (last updated search in October, 2014) by applying a sensitive search strategy using search terms: ("coronary heart disease" or "myocardial infarction" or "MI" or "acute myocardial infarction" or "AMI") and ("*ABCA1*" or "Adenosine Triphosphate-binding cassette transporter A1" or "*CRP*" or "CRP C-reactive protein" or "genetic polymorphism"). Manual searches were conducted to retrieve other cross-references.

Inclusion and exclusion criteria
--------------------------------

Published studies retrieved met these inclusion criteria: (1) research topic: correlations between *ABCA1* R219K (rs2230806) or *CRP* +1059G/C (rs1800947) gene polymorphisms and susceptibility to CHD; (2) study type: case-control studies; (3) subject investigated: CHD patients and normal controls; (4) relevant indicators: allele and genotype frequency; and (5) studies published in Chinese or English. Only the latest complete study was considered when the extracted studies were published by the same authors. The exclusion criteria were: (1) insufficient data; (2) animal studies; (3) duplicate publications; and (4) absence of data integrity.

Data extraction and quality assessment
--------------------------------------

Two reviewers screened each study independently to determine whether it met the inclusion criteria. Disagreements between the investigators were resolved by discussion with a third investigator. Collected information included: the first author, publication year, country, age, sex, gene, number of case and controls, ethnicity, language, genotyping method, detection method, and SNP site. The study quality was assessed by 2 or more investigators independently using the Critical Appraisal Skill Program (CASP) criteria (*<http://www.casp-uk.net/>*).

Statistical analysis
--------------------

Comprehensive Meta-analysis 2.0 (Biostat Inc., Englewood, New Jersey, USA) was used for data analysis. The differences in allele and genotype frequency of *ABCA1* R219K (rs2230806) and *CRP* +1059G/C (rs1800947) polymorphisms were estimated by odds ratio (OR) with 95% confidence intervals (95%CI). The Z test was conducted to assess the overall effect values \[[@b25-medscimonit-22-2999]\]. Forest plots were used to reflect the comparisons of ORs with 95%CI between the 2 groups. The heterogeneity was determined using the Cochran's Q-statistic (*P*\<0.05 was considered significant) and *I^2^* test (0%, no heterogeneity; 100%, maximal heterogeneity) \[[@b26-medscimonit-22-2999],[@b27-medscimonit-22-2999]\]. The random-effects model was used in case of significant heterogeneity (*P*\<0.05 or *I^2^* test exhibited \>50%); otherwise, the fixed-effects model was used \[[@b28-medscimonit-22-2999]\]. The potential sources of heterogeneity were evaluated by univariate and multivariate meta-regression analysis, confirmed by Monte Carlo method \[[@b26-medscimonit-22-2999],[@b29-medscimonit-22-2999]\]. Sensitivity analysis was conducted to assess whether a study had significant influences on the overall results by deleting each study sequentially. Funnel plots, classic fail-safe N, and Egger's linear regression test were used to define the publication bias \[[@b30-medscimonit-22-2999],[@b31-medscimonit-22-2999]\]. All tests were 2-sided and *P*\<0.05 indicated a statistically significant difference.

Results
=======

Baseline characteristics
------------------------

Our search identified 139 published records, from which we excluded duplicates (n=17), letters, reviews, or meta-analysis (n=4), non-human studies (n=4), and studies in languages other than Chinese or English (n=3). The remaining 111 studies were reviewed and a total of 78 studies were removed because they were not case-control (n=10), they were unpublished studies (n=2), or they were irrelevant to *ABCA1* and *CRP* gene (n=35) or irrelevant to CHD (n = 31). After further assessment, 22 studies were removed for not containing enough information. Following this multi-step screening process, 11 studies with 3053 CHD patients and 3403 healthy controls were finally selected after a full-text analysis \[[@b20-medscimonit-22-2999],[@b23-medscimonit-22-2999],[@b32-medscimonit-22-2999]--[@b40-medscimonit-22-2999]\]. The 11 studies were published from 2005 to 2013, with sample sizes ranging from 121 to 1900. The gene *loci* of *ABCA1* R219K (rs2230806) and *CRP +*1059G/C (rs1800947) are presented in [Figure 1](#f1-medscimonit-22-2999){ref-type="fig"}. Among the 11 studies, 3 studies were performed in Caucasians, 7 studies were performed in Asians, and 1 study was performed in Africans. Polymerase chain reaction with restriction fragment length polymorphism (PCR-RFLP) was a common genotyping method among the studies. The baseline characteristics and selection procedure for the 11 studies are presented in [Table 1](#t1-medscimonit-22-2999){ref-type="table"} and [Figure 2](#f2-medscimonit-22-2999){ref-type="fig"}, respectively.

Meta-analysis of correlation between *ABCA1* R219K (rs2230806) polymorphism and susceptibility to CHD
-----------------------------------------------------------------------------------------------------

Five studies reported the correlation between *ABCA1* R219K (rs2230806) polymorphism and susceptibility to CHD. Considering the significant heterogeneity among studies, the random-effects model was used (allele model: *I^2^*=69.552%, *P*=0.011; dominant model: *I^2^*=59.318%, *P*=0.043). As shown in [Figure 3A, 3B](#f3-medscimonit-22-2999){ref-type="fig"}, and [Table 2](#t2-medscimonit-22-2999){ref-type="table"}, the *ABCA1* R219K (rs2230806) polymorphism significantly increased the susceptibility to CHD (allele model: OR=0.729, 95% CI=0.559\~0.949, *P*=0.019; dominant model: OR=0.698, 95% CI=0.507\~0.961, *P*=0.027). Meta-regression analysis showed that publication year, ethnicity, and sample size were neither the heterogeneous sources nor the key factors that influenced the overall effect size (both *P*\> 0.05) ([Figure 4A--4C](#f4-medscimonit-22-2999){ref-type="fig"}, [Table 3A](#t3A-medscimonit-22-2999){ref-type="table"}).

Meta-analysis of correlation between *CRP* +1059G/C (rs1800947) polymorphism and susceptibility to CHD
------------------------------------------------------------------------------------------------------

A total of 6 studies reported the correlation between *CRP* +1059G/C (rs1800947) polymorphism and susceptibility to CHD. The random-effects model was used due to significant heterogeneity (allele model: *I^2^*=78.465%, *P*\<0.001; dominant model: *I^2^*=76.652%, *P*=0.001). The results of the present meta-analysis failed to show any significant correlation between the polymorphism of *CRP* +1059G/C (rs1800947) and susceptibility to CHD (allele model: OR=1.170, 95% CI=0.782\~1.751, *P*=0.444; dominant model: OR=1.175, 95% CI=0.768\~1.797, *P*=0.457) ([Figure 3C, 3D](#f3-medscimonit-22-2999){ref-type="fig"}, [Table 2](#t2-medscimonit-22-2999){ref-type="table"}). Meta-regression analysis suggested that publication year, ethnicity and sample size are not heterogeneous sources or key factors influencing the overall effect size (both *P*\>0.05) ([Figure 4D--4F](#f4-medscimonit-22-2999){ref-type="fig"}, [Table 3B](#t3B-medscimonit-22-2999){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

The sensitivity analysis showed that no single study significantly affected the pooled ORs of correlations between *CRP* +1059G/C (rs1800947) polymorphism and susceptibility to CHD. Except for the studies by Li et al. 2005, Yu et al. 2008 and Wang et al. 2013, no single study affected the pooled ORs of correlations between *ABCA1* R219K (rs2230806) polymorphism and susceptibility to CHD ([Figure 5](#f5-medscimonit-22-2999){ref-type="fig"}). The shape of funnel plots did not reveal any evidence of funnel plot asymmetry and the statistical results did not show any publication bias. Classic fail-safe N and Egger's linear regression test confirmed that there was no significant publication bias (all *P*\>0.05) ([Figure 6](#f6-medscimonit-22-2999){ref-type="fig"}).

Discussion
==========

To investigate the associations of *CRP* and *ABCA1* gene polymorphisms with CHD susceptibility, we selected 2 polymorphisms, 1059G \>C (rs1800947) of *CRP* and R219K (rs2230806) of *ABCA1,* and performed a comprehensive meta-analysis of the available data. The results of the present meta-analysis suggest that R219K (rs2230806) polymorphism of *ABCA1* is associated with a significantly increased risk of CHD. The influence of *ABCA1* on plasma lipid levels may be a potential mechanism by which *ABCA1* R219K polymorphism is involved with the risk of CHD \[[@b4-medscimonit-22-2999]\]. Disorders of lipid homeostasis are important in the development and progression of CHD and hyperlipidemia is a major risk factor for CHD \[[@b8-medscimonit-22-2999]\]. Atherosclerosis, the major cause of CHD, is characterized by accumulation of unbalanced lipid in the arterial wall, resulting in narrowing of the vessel lumen \[[@b10-medscimonit-22-2999]\]. The major pathogenesis of atherosclerosis is reverse cholesterol transport (RCT) mediated by HDL-C, which facilitates cholesterol efflux from peripheral cells \[[@b41-medscimonit-22-2999]\]. *ABCA1* stimulates cholesterol efflux to lipid-poor HDL apolipoproteins, the initial step in reverse cholesterol transport \[[@b4-medscimonit-22-2999],[@b42-medscimonit-22-2999]\]. High plasma LDL-C concentration contributes to the development of atherosclerotic plaques, whose break-up or rupture result in angiemphraxis and ischemic cardiac events \[[@b12-medscimonit-22-2999]\]. Another probable mechanism is that R219K polymorphism enhances ABCA1 activity, leading to mediation of cholesterol efflux, independent of plasma HDL-C levels \[[@b4-medscimonit-22-2999]\]. Several case-control studies investigated the association between *ABCA1* R219K polymorphism and the susceptibility to CHD, but the findings were conflicting \[[@b4-medscimonit-22-2999],[@b17-medscimonit-22-2999]\]. Consistent with our results, the R219K variant was shown to modulate the HDL-C response to CHD medication in patients with CHD, suggesting a possible association between R219K gene polymorphism and CHD \[[@b24-medscimonit-22-2999],[@b33-medscimonit-22-2999]\]. Studies investigating the association between polymorphisms of the *CRP* gene and atherosclerosis suggest that variations in CRP might be involved in the pathogenesis of CHD and could be helpful in predicting CHD \[[@b18-medscimonit-22-2999],[@b32-medscimonit-22-2999],[@b43-medscimonit-22-2999]\]. In the present meta-analysis, we found no significant association between *CRP* 1059G \>C (rs1800947) polymorphism and CHD susceptibility. In accordance with our result, a previous study also found that *CRP* 1059G/C gene variation resulted in higher plasma CRP levels but was not associated with risk for AMI and CHD \[[@b20-medscimonit-22-2999]\].

Some limitations should be noted while interpreting the results of the present meta-analysis. First, inter-study heterogeneity still existed in this meta-analysis even though we minimized its likelihood by performing a sensitive search strategy. Second, as a retrospective study, the present meta-analysis may have recall or selection bias, possibly influencing the stability of our results. Third, the limited access to the original data from some studies restrained our further investigation of the potential interactions between other factors and CHD risks, such as gene-environment and gene-gene interactions. Fourth, most of the 11 eligible studies were performed in Asians and only 1 study was performed in Africans. Finally, the language of included studies was limited to English and Chinese, and studies published in other languages were excluded.

Conclusions
===========

In summary, our meta-analysis shows that *ABCA1* R219K (rs2230806) polymorphism is associated with susceptibility to CHD, but *CRP* +1059G/C (rs1800947) is not correlated with CHD risk. Furthermore, gene-to-gene and gene-to-environment interactions should also be investigated in future studies. A better understanding of the mechanism of CHD pathogenesis will be beneficial in future studies on prevent CHD progression.
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###### 

The baseline characteristics of 11 eligible studies in present meta-analysis investigating the correlation of *ABCA1* R219K and *CRP* +1059G/C polymorphisms with the susceptibility of coronary heart disease.

  First author         Year   Country   Ethnicity    Disease   Gender (M/F)   Age (years)   Gene          SNP                     
  -------------------- ------ --------- ------------ --------- -------------- ------------- ------------- ------------- --------- ---------------------
  Li Y                 2005   China     Asians       CHD       237/159        248/169       60.1±8.8      59.4±7.6      *ABCA1*   R219K (rs2230806)
  Balistreri CR        2006   Italy     Caucasians   MI        106/0          120/0         41 (20--46)   39 (20--50)   *CRP*     +1059G/C(rs1800947)
  Martin M             2006   Spain     Caucasians   MI        170/0          NR            43±5          NR            *ABCA1*   R219K (rs2230806)
  Zhao BC              2006   China     Asians       MI        99/52          40/40         44--75        42--76        *CRP*     +1059G/C(rs1800947)
  Pai JK               2008   USA       Caucasians   CHD       266/249        531/498       62.75±0.11    62.7±0.08     *CRP*     +1059G/C(rs1800948)
  Yu B                 2008   China     Asians       MI        49/0           72/0          55.8±3.8      51.4±4.0      *ABCA1*   R219K (rs2230806)
  Li J                 2009   China     Asians       CHD       176/189        NR            63±14         61±13         *ABCA1*   R219K (rs2230806)
  Sun DL               2011   China     Asians       CHD       81/17          99/26         55.69±11.48   49.97±11.64   *CRP*     +1059G/C(rs1800947)
  Akbarzadeh Najar R   2012   Iran      Asians       MI        478/472        475/475       52.96±1.89    49.85±0.36    *CRP*     +1059G/C(rs1800947)
  Ghattas MH           2012   Egypt     Africans     MI        90/60          93/62         47.7±4.85     49.10±10.30   *CRP*     +1059G/C(rs1800947)
  Wang JR              2013   China     Asians       MI        59/44          67/47         65.9±13.1     63.8±11.9     *ABCA1*   R219K (rs2230806)

MI -- myocardial infarction; CHD -- coronary heart disease; M -- male; F -- female; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism; NR -- no reference.

###### 

Comparisons of genotype and allele frequencies between the case and the control groups in present meta-analysis investigating the correlation of *ABCA1* R219K and *CRP* +1059G/C polymorphisms with the susceptibility to coronary heart disease.

  Gene Model                               *ABCA1* (rs2230806)   *CRP* (rs1800947)                                  
  ---------------------------------------- --------------------- ------------------- ------- ------- -------------- -------
  M allele *vs.* W allele (Allele model)   0.729                 0.559--0.949        0.019   1.170   0.782--1.751   0.444
  WM + MM *vs.* WW (Dominant model)        0.698                 0.507--0.961        0.027   1.175   0.768--1.797   0.457
  MM *vs.* WW (Homozygous model)           0.552                 0.331--0.921        0.023   1.265   0.738--2.169   0.392
  WM *vs.* MM (Heterozygous model)         1.288                 0.991--1.676        0.059   0.841   0.475--1.488   0.552
  MM *vs.* WW + WM (Recessive model)       0.695                 0.543--0.890        0.004   1.252   0.731--2.145   0.413

OR -- odds ratio; 95% CI -- 95% confidential intervals.

###### 

Meta-regression analyses of potential sources of heterogeneity for *ABCA1* R219K by analyzing publication year, ethnicity and sample size.

  Heterogeneity factors   Coefficient   SE      t       *P* (Adjusted)   95% CI   
  ----------------------- ------------- ------- ------- ---------------- -------- -------
  Year                    0.117         0.081   1.46    0.545            −0.906   1.140
  Ethnicity               −1.190        0.546   −2.18   0.355            −8.133   5.753
  Sample size             0.002         0.001   1.92    0.431            −0.009   0.013

###### 

Meta-regression analyses of potential sources of heterogeneity for *CRP* +1059G/C by publication year, ethnicity and sample size.

  Heterogeneity factors   Coefficient   SE      t       *P* (Adjusted)   95% CI   
  ----------------------- ------------- ------- ------- ---------------- -------- -------
  Year                    −0.049        0.129   −0.38   0.914            −0.604   0.506
  Ethnicity               −0.492        0.459   −1.08   0.472            −2.449   1.465
  Sample size             −0.001        0.001   −0.20   0.982            −0.001   0.001

SE -- standard error; LL -- lower limit; UL -- upper limit.
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